# Biodesix Inc: overview BDSX · Nasdaq · CIK 1439725 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/bdsx.md) · [Financials](/companies/bdsx/financials.md) · [Filings](/companies/bdsx/filings.md) · [Insiders](/companies/bdsx/insiders.md) Latest reported revenue: [$26.9m](/filings/0001193125-26-335036.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-335036). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [18.2](/filings/0001193125-25-262532.md) | [20.4 d](/filings/0001193125-26-076547.md) | [18.0](/filings/0001193125-26-203960.md) | [20.0](/filings/0001193125-26-335036.md) | [21.8](/filings/0001193125-25-262532.md) | [28.8 d](/filings/0001193125-26-076547.md) | [25.6](/filings/0001193125-26-203960.md) | [26.9](/filings/0001193125-26-335036.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(47.3%)](/filings/0001193125-25-262532.md) | [(32.5%) d](/filings/0001193125-26-076547.md) | [(50.9%)](/filings/0001193125-26-203960.md) | [(48.6%)](/filings/0001193125-26-335036.md) | [(32.4%)](/filings/0001193125-25-262532.md) | [(6.8%) d](/filings/0001193125-26-076547.md) | [(24.3%)](/filings/0001193125-26-203960.md) | [(20.1%)](/filings/0001193125-26-335036.md) | | Net margin | % | [(56.5%)](/filings/0001193125-25-262532.md) | [(40.4%) d](/filings/0001193125-26-076547.md) | [(61.8%)](/filings/0001193125-26-335036.md) | [(57.3%)](/filings/0001193125-26-335036.md) | [(40.0%)](/filings/0001193125-25-262532.md) | [(13.8%) d](/filings/0001193125-26-076547.md) | [(30.5%)](/filings/0001193125-26-335036.md) | [(27.1%)](/filings/0001193125-26-335036.md) | | Diluted EPS | $ per share | [(1.40)](/filings/0001193125-25-262532.md) | not reported | [(1.52)](/filings/0001193125-26-203960.md) | [(1.56)](/filings/0001193125-26-335036.md) | [(1.16)](/filings/0001193125-25-262532.md) | not reported | [(0.81)](/filings/0001193125-26-203960.md) | [(0.71)](/filings/0001193125-26-335036.md) | | Free cash flow | $m | [(10.9) d](/filings/0001193125-25-262532.md) | [(4.9) d](/filings/0001193125-26-076547.md) | [(8.7)](/filings/0001193125-26-203960.md) | [(6.6) d](/filings/0001193125-26-335036.md) | [(8.9) d](/filings/0001193125-25-262532.md) | [0.7 d](/filings/0001193125-26-076547.md) | [(10.2)](/filings/0001193125-26-203960.md) | [(1.8) d](/filings/0001193125-26-335036.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [54.5](/filings/0000950170-23-006092.md) | [38.2](/filings/0000950170-24-023513.md) | [49.1](/filings/0000950170-25-030835.md) | [71.3](/filings/0001193125-26-076547.md) | [88.5](/filings/0001193125-26-076547.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(75.1%)](/filings/0000950170-23-006092.md) | [(132.4%)](/filings/0000950170-24-023513.md) | [(84.2%)](/filings/0000950170-25-030835.md) | [(48.4%)](/filings/0001193125-26-076547.md) | [(31.5%)](/filings/0001193125-26-076547.md) | | Net margin | % | [(79.2%)](/filings/0000950170-23-006092.md) | [(171.3%)](/filings/0000950170-24-023513.md) | [(106.2%)](/filings/0000950170-25-030835.md) | [(60.2%)](/filings/0001193125-26-076547.md) | [(39.8%)](/filings/0001193125-26-076547.md) | | Diluted EPS | $ per share | [(1.58)](/filings/0000950170-23-006092.md) | [(1.55)](/filings/0000950170-24-023513.md) | [(0.64)](/filings/0000950170-25-030835.md) | [(6.64)](/filings/0001193125-26-076547.md) | [(4.67)](/filings/0001193125-26-076547.md) | | Free cash flow | $m | [(30.5)](/filings/0000950170-23-006092.md) | [(48.3)](/filings/0000950170-24-023513.md) | [(45.8)](/filings/0000950170-25-030835.md) | [(51.9)](/filings/0001193125-26-076547.md) | [(23.5)](/filings/0001193125-26-076547.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bdsx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [AIGH Capital Management LLC](/funds/1835943.md) | 2026-06-30 | $15.3m | 678,328 | | Reduced −80,000 | | [Soleus Capital Management, L.P.](/funds/1802630.md) | 2026-06-30 | $13.2m | 585,958 | | Added +169,359 | | [Telemark Asset Management, LLC](/funds/1420816.md) | 2026-06-30 | $11.0m | 489,824 | | Unchanged | | [Aberdeen Group plc](/funds/1716774.md) | 2026-06-30 | $8.8m | 388,639 | | Reduced −69,799 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $6.4m | 284,169 | | Added +29,008 | | [ESSEX INVESTMENT MANAGEMENT CO LLC](/funds/201772.md) | 2026-06-30 | $5.5m | 241,915 | | Added +109,829 | | [Opaleye Management Inc.](/funds/1595855.md) | 2026-06-30 | $4.1m | 180,000 | | Reduced −58,047 | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $2.6m | 116,199 | | Reduced −25,437 | | [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $2.5m | 108,694 | | New +108,694 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $2.1m | 91,506 | | Added +64,475 | ## Recent filings [All 591 filings](/companies/bdsx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-05 | 20:05 ET | [10-Q](/filings/0001193125-26-335036.md) | Quarterly report, period 2026-06-30 | 0001193125-26-335036 | | 2026-08-05 | 20:02 ET | [8-K](/filings/0001193125-26-335010.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-335010 | | 2026-05-20 | 20:18 ET | [8-K](/filings/0001193125-26-232631.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-232631 | | 2026-05-04 | 20:05 ET | [10-Q](/filings/0001193125-26-203960.md) | Quarterly report, period 2026-03-31 | 0001193125-26-203960 | | 2026-05-04 | 20:03 ET | [8-K](/filings/0001193125-26-203936.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-203936 | | 2026-04-09 | 20:14 ET | [DEF 14A](/filings/0001193125-26-149633.md) | Proxy statement, period 2026-05-19 | 0001193125-26-149633 | | 2026-02-26 | 21:06 ET | [10-K](/filings/0001193125-26-076547.md) | Annual report, period 2025-12-31 | 0001193125-26-076547 | | 2026-02-26 | 21:02 ET | [8-K](/filings/0001193125-26-076521.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-076521 | | 2026-01-27 | 19:28 ET | [SCHEDULE 13D/A](/filings/0000905148-26-000363.md) | Ownership report, active investor, amended | 0000905148-26-000363 | | 2026-01-12 | 17:04 ET | [8-K/A](/filings/0001193125-26-010114.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-010114 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-076547.md), filed Feb 26, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/07f76f07-7f07-4f2a-a911-c5dc78d12135) ## About the filer - CIK: 1439725 - Tickers: BDSX - Exchange: Nasdaq - SIC code: 8071 Services-Medical Laboratories - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.